- Home
- WIW vs CSTL Comparison
WIW vs CSTL Comparison
Compare WIW & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIW
- CSTL
- Stock Information
- Founded
- WIW 2004
- CSTL 2007
- Country
- WIW United States
- CSTL United States
- Employees
- WIW N/A
- CSTL N/A
- Industry
- WIW Finance Companies
- CSTL Medical Specialities
- Sector
- WIW Finance
- CSTL Health Care
- Exchange
- WIW Nasdaq
- CSTL Nasdaq
- Market Cap
- WIW 536.0M
- CSTL 471.5M
- IPO Year
- WIW N/A
- CSTL 2019
- Fundamental
- Price
- WIW $8.75
- CSTL $14.65
- Analyst Decision
- WIW
- CSTL Strong Buy
- Analyst Count
- WIW 0
- CSTL 6
- Target Price
- WIW N/A
- CSTL $37.67
- AVG Volume (30 Days)
- WIW 229.9K
- CSTL 378.5K
- Earning Date
- WIW 01-01-0001
- CSTL 08-04-2025
- Dividend Yield
- WIW 11.14%
- CSTL N/A
- EPS Growth
- WIW N/A
- CSTL N/A
- EPS
- WIW N/A
- CSTL N/A
- Revenue
- WIW N/A
- CSTL $347,083,000.00
- Revenue This Year
- WIW N/A
- CSTL N/A
- Revenue Next Year
- WIW N/A
- CSTL $1.62
- P/E Ratio
- WIW N/A
- CSTL N/A
- Revenue Growth
- WIW N/A
- CSTL 38.43
- 52 Week Low
- WIW $8.01
- CSTL $14.61
- 52 Week High
- WIW $9.37
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- WIW 51.83
- CSTL 25.04
- Support Level
- WIW $8.67
- CSTL $16.00
- Resistance Level
- WIW $8.79
- CSTL $16.67
- Average True Range (ATR)
- WIW 0.06
- CSTL 0.81
- MACD
- WIW -0.01
- CSTL -0.30
- Stochastic Oscillator
- WIW 50.00
- CSTL 0.79
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.